HemoSense competitors

Accredited public company director. Dynamic, creative, growth and success oriented leader. Proven experience building and leading an organization from distress to profitability while increasing shareholder value 5x in 24 months.

Mr. Ward has been a member of our Board of Directors since 2013 and has served as Chairman since November 2014. Mr. Ward served as our Interim President and Chief Executive Officer commencing in November 2015. In August 2016, Mr. Ward was appointed President and Chief Executive Officer. Since 2013, Mr. Ward has been one of the Managing Directors at SightLine Partners. Following his appointment as our President and Chief Executive Officer, Mr. Ward continues to be a Managing Director of Sightline Opportunity Management Fund II, LLC, and may provide limited advisory and consulting services to Sightline Partners in this capacity.

Michael Feldschuh is an Exec VP:Bus Dev & Strategic Initiatives at DAXOR CORP and Chairman/President/CEO at DAXOR CORP. He has worked as Managing Dir/Portfolio Manager at Millennium Mgmt LLC, Chief Investment Officer at ARISTARC CAPITAL LLC, and Mng Dir/Portfolio Mgr at Morgan Stanley. Michael attended Columbia University.

George Lemaitre is a Chairman/CEO at LEMAITRE VASCULAR INC, Manager at Lemaitre Family LLC, and Board Member at VASCUTECH INC and is based in Greater Boston Area. He has worked as Board Member at LEMAITRE VASCULAR INC, Credit Analyst at Connecticut National Bank/Bridgeport CT, and Associate at MCCOWN DE LEEUW & CO. George works or has worked as Board of Directors at LEMAITRE VASCULAR INC, Owner at LEMAITRE VASCULAR INC, and BOARD MEMBER at Stanford Univ Graduate Schl of Bussiness Management. He attended Stanford Graduate School of Business between 1990 and 1992, Phillips Academy Andover between 1978 and 1982, and Stanford University between 1982 and 1986.

Mr. Dominick C. Colangelo joined Promedior in December 2008 with fifteen years of pharmaceutical industry experience, including nearly a decade with Eli Lilly and Company. During his career, Mr. Colangelo has held a variety of executive positions of increasing responsibility in finance, product development, pharmaceutical operations, and corporate business development. During his tenure at Eli Lilly and Company, Mr. Colangelo held positions as an international tax attorney in the finance organization and as Director of Strategy and Business Development for Lilly’s Diabetes and Growth Disorders Product Group. He also served as a founding Managing Director of Lilly Ventures. Mr. Colangelo received a B.S.B.A. degree in Accounting from the State University of New York at Buffalo and a J.D. degree from the Duke University School of Law.

Avi Pelossof was appointed Global President of our infectious disease business unit in March 2013, after serving as Vice President of that business from February 2008 to February 2013. Mr. Pelossof joined Alere as Vice President, Blood-Borne Pathogens in January 2007 and served in that role until January 2008. Mr. Pelossof has more than 20 years of experience in diagnostics, global health and international finance, including senior roles at Chembio Diagnostic Systems, a manufacturer of diagnostic tests for infectious diseases, and Citigroup.

Richard 'Rich' Mott is a Chairman at Conventus Orthopaedics Inc, President/CEO at Kyphon, and Board Member at Vertiflex. He has worked as Board Member at Alfred University, Board Member at Conventus Orthopaedics Inc, and VP/General Manager at Greatbatch Scientific. Richard attended Alfred University and Harvard University.

Experienced Biopharma & Technology Founder, Executive & Board Member with a demonstrated history of working in the Life Sciences & Information Technology industries across continents.